Distorsiones al Mercado

Los efectos de las regulaciones en la economía, tan de moda en la Argentina Productivista (visto en Instapundit):

Germany has a new chancellor, a new government, and a new opportunity to restart the engine of innovation that once positioned it as one of the most powerful and innovative economies in the world. German Chancellor Angela Merkel, who will be in the US this week for her first official state visit, should seize this opportunity before it slips away.

A good place to start would be in the bioscience and biopharmaceutical spheres. Nowhere is the decline of German innovation more obvious than there. German firms once dominated the biopharmaceutical field. Known as the “medicine chest of Europe,” German drug makers spawned U.S. divisions that are now multinationals in their own right. But today, as The Philadelphia Inquirer detailed in a recent series, there is not one German company among the top ten drug-makers.

German medical and biopharmaceutical firms are now lagging far behind their younger cousins in the U.S. when it comes to developing the new “wonder drugs” that are shaping the 21st century: By some estimates, U.S. labs are churning out 70 percent of all new drugs.

A range of shortsighted government policies did much of the damage.